TG Therapeutics Q4 2022 Earnings Report
Key Takeaways
TG Therapeutics reported product revenue of approximately zero for the fourth quarter of 2022. R&D expenses were $29.6 million, and SG&A expenses were $22.5 million. The net loss for the quarter was $53.0 million. Cash, cash equivalents and investment securities were $174.1 million as of December 31, 2022.
BRIUMVI was approved by the FDA for the treatment of relapsing forms of multiple sclerosis (RMS).
BRIUMVI was commercially launched and made available for patients and physicians.
Additional data from the ULTIMATE I and II Phase 3 trials were presented at medical conferences.
The company anticipates that its cash, cash equivalents and investment securities as of December 31, 2022, will be sufficient to fund planned operations into mid-2024.
TG Therapeutics
TG Therapeutics
Forward Guidance
TG Therapeutics anticipates that its cash, cash equivalents and investment securities as of December 31, 2022, combined with available capacity under its existing term loan facility and projected revenues, will be sufficient to fund the Company’s planned operations into mid-2024.